Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents

被引:113
作者
Ireson, CR
Chander, SK
Purohit, A
Perera, S
Newman, SP
Parish, D
Leese, MP
Smith, AC
Potter, BVL
Reed, RJ [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Fac Med, Endocrinol & Metab Med & Sterix Ltd, London W2 1NY, England
[2] Univ Bath, Dept Pharm & Pharmacol, Med Chem & Sterix Ltd, Bath BA2 7AY, Avon, England
关键词
2-methoxyoestradiol; 2-methoxyoestradiol-bis-sulphamate; breast cancer; sulphatase; sulphatase inhibitor; pharmacokinetics;
D O I
10.1038/sj.bjc.6601591
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2-Methoxyoestradiol (2-MeOE2) is an endogenous oestrogen metabolite that inhibits the proliferation of cancer cells in vitro, and it is also antiangiogenic. In vivo 2-MeOE2, when administered at relatively high doses, inhibits the growth of tumours derived from breast cancer cells, sarcomas and melanomas. Sulphamoylated derivatives of 2-MeOE2 are more potent inhibitors of in vitro breast cancer cell growth than 2-MeOE2. In the present study, we have compared the pharmacokinetic profiles and metabolism of 2-MeOE2 and its sulphamoylated derivative, 2-methoxyoestradiol-bis-sulphamate (2-MeOE2bisMATE), in adult female rats. Their ability to inhibit tumour growth was compared in nude mice bearing xenografts derived from MDA-MB-435 (oestrogen receptor negative) melanoma cancer cells. After a single oral 10 mg kg(-1) dose of 2-MeOE2bisMATE, significant concentrations of this compound were still detectable at 24 h. In contrast, no 2-MeOE2 or metabolites were detected in plasma at any time after a 10 mg kg(-1) oral dose. Thus, the bioavailability of 2-MeOE2 is very low, whereas for 2-MeOE2bisMATE it was 85%. No significant metabolites of 2-MeOEbisMATE were detected in plasma after oral or intravenous dosing, showing that this drug is resistant to metabolism. In the tumour efficacy model, oral administration of 2-MeOE2bisMATE, at 20 mg kg(-1) day(-1) daily for 28 days, almost completely inhibited tumour growth. Inhibition of tumour growth was maintained for a further 28 days after the cessation of dosing, At this dose level, 2-MeOE2 did not inhibit tumour growth. The resistance to metabolism shown by 2-MeOE2bisMATE and its ability to inhibit tumour growth in vivo suggest that this compound should have considerable potential for development as a novel anticancer drug.
引用
收藏
页码:932 / 937
页数:6
相关论文
共 30 条
[1]   Pharmacokinetics of oestrone-3-O-sulphamate [J].
Aragones, MIH ;
Purohit, A ;
Parish, D ;
Sahm, UG ;
Pouton, CW ;
Potter, BVL ;
Reed, MJ .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1996, 58 (5-6) :611-617
[2]  
Ball P, 1980, Acta Endocrinol Suppl (Copenh), V232, P1
[3]  
BRADLOW HL, 1998, J ENDOCRINOL, V150, pS259
[4]   2-Methoxymethylestradiol: a new 2-methoxy estrogen analog that exhibits antiproliferative activity and alters tubulin dynamics [J].
Brueggemeier, RW ;
Bhat, AS ;
Lovely, CJ ;
Coughenour, HD ;
Joomprabutra, S ;
Weitzel, DH ;
Vandre, DD ;
Yusuf, F ;
Burak, WE .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2001, 78 (02) :145-156
[5]  
Chander SK, 2003, P AM ASS CANC RES AB, V44, P1156
[6]   2-METHOXYESTRADIOL, AN ENDOGENOUS MAMMALIAN METABOLITE, INHIBITS TUBULIN POLYMERIZATION BY INTERACTING AT THE COLCHICINE SITE [J].
DAMATO, RJ ;
LIN, CM ;
FLYNN, E ;
FOLKMAN, J ;
HAMEL, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3964-3968
[7]  
Dingli D, 2002, CLIN CANCER RES, V8, P3948
[8]  
Elger W, 1998, Expert Opin Investig Drugs, V7, P575, DOI 10.1517/13543784.7.4.575
[9]   Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application [J].
Elger, W ;
Schwarz, S ;
Hedden, AM ;
Reddersen, G ;
Schneider, B .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 55 (3-4) :395-403
[10]   Further evidence to support the melanocytic origin of MDA-MB-435 [J].
Ellison, G ;
Klinowska, T ;
Westwood, RFR ;
Docter, E ;
French, T ;
Fox, JC .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 2002, 55 (05) :294-299